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for respondents who received the educational materials (6.4
more correct answers after the intervention, n = 341, p <
0.0001). Almost 60% reported reading the educational materi-
als. Respondents whom reported reading the materials had an
increase of 8.9 more correct answers after the intervention
(16.8% increase) (n = 194, p < 0.0001) compared to 3.1 more
correct answers among those whom reported not reading the
materials (6.1% increase) (n = 147, p < 0.0001). Respondents
with anemia (n = 159) had signiﬁcantly greater baseline knowl-
edge compared to those without anemia (n = 182). The number
of correct answers increased by 11.0% in respondents with
anemia and increased by 13.4% in those without anemia.
However, there was no signiﬁcant difference in knowledge
increase between respondents with and without anemia. CON-
CLUSION: An Internet-based survey and educational program
is a rapid, efﬁcient, and effective method to increase patient
knowledge regarding anemia. The intervention is equally effec-
tive among patients with and without anemia.
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OBJECTIVES: The objectives of this paper are to explain and
illustrate the usefulness and limitations of logit models with rare
events and to investigate alternatives to improve the estimators.
We also propose a test to determine whether underestimation of
coefﬁcients is statistically signiﬁcant METHODS: We examined
two correction methods to solve possible “rare event” bias in
logit estimation: a) prior correction, which involves computing
the usual logistic regression and correcting the estimation based
on prior information; and b) weighting, which involves weight-
ing the data to compensate for differences in the sample and
prior fraction of ones induced by choice-based sampling. In order
to determine whether there is a rare-event bias in our sample, we
developed a Hausman kind of test to compare coefﬁcients from
logit regression with coefﬁcients from re-logit regression. To
apply the methodology, we conducted a retrospective cohort
study analyzing hospitalization for new cerebrovascular events
in elderly. RESULTS: The ﬁnal study sample comprised 1638
patients using Drug Class A and 2419 patients using Drug Class
B. The probability of having a cerebrovascular event among
Drug Class B patients was 1.76 times higher than the probabil-
ity of having such an event among Drug Class A patients. This
ratio was not signiﬁcant (p = 0.236). The odds ratio after prior
correction was 1.96 and after weighting was 2.09. A compari-
son of the estimates using the Hausman type of test found that
the rare-event bias was not signiﬁcant. CONCLUSION: We
examined two correction methods and proposed a test to deter-
mine whether underestimation is statistically signiﬁcant. If we
fail to reject the proposed test, logit estimates can be used since
the underestimation is not statistically signiﬁcant. Otherwise,
prior correction is preferable if the sample size is small (n < 200),
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OBJECTIVES: To evaluate the effect of adding medical claims
data to predictive models based on pharmacy claims data. To
examine models predicting future total health care costs and
jumps in total health care costs. METHODS: Multivariate
regression models were developed to predict subsequent year
total health care costs and changes in health care costs for each
plan participant (baseline January 1 to December 31, 2002;
follow-up January 1 to December 31, 2003). De-identiﬁed data
from continuously eligible plan participants from two large
employer groups were studied (n = 141,153). Performance of
predictive models utilizing pharmacy claims data only was com-
pared with performance of models utilizing medical claims in
addition to pharmacy claims data. Both types of models included
basic demographic information of plan participants. RESULTS:
When estimating next year total health care costs, predictive
models using both medical and pharmacy claims data perform
slightly better than models with only pharmacy information 
(R2 = 0.32 for medical and pharmacy versus R2 = 0.25 for 
pharmacy only). When estimating jumps in total health care
costs from the current year to the next year, predictive models
using both medical and pharmacy claims are signiﬁcantly 
superior to the models based on pharmacy claims data only 
(R2 = 0.22 for medical and pharmacy versus R2 = 0.02 for 
pharmacy only). CONCLUSIONS: The addition of medical
claims data to the pharmacy-based predictive models results in
slightly more accurate identiﬁcation of future total health care
costs. In order to best predict plan participants who signiﬁcantly
jump in total health care costs, detailed medical claims data are
essential.
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